| ADT | Androgen-Deprivation Therapy |
| AR | Androgen Receptor |
| ARSi | Androgen-Receptor Signaling Inhibitors |
| AR-V7 | Androgen-receptor Splice Variant 7 messenger RNA |
| ASCO | American Society Clinical Oncology |
| ASR | Age Standardized Rate |
| BS | Bone Scintigraphy |
| CRPC | Castration-Resistant Prostate Cancer |
| CSPC | Castration-Sensitive Prostate Cancer |
| CT | Computed Tomography |
| dMMR | Mismatch Repair Deficient |
| EAU | European Association of Urology |
| FDA | US Food and Drug Administration |
| MSI-H | Microsatellite instability-high |
| mCRPC | Metastatic Castration-Resistant Prostate Cancer |
| mCSPC | Metastatic Castration-Sensitive Prostate Cancer |
| MRI | Magnetic Resonance Imaging |
| PCa | Prostate Cancer |
| PET | Positron Emission Tomography |
| PS | Performance Status |
| PSMA | Prostate-Specific Membrane Antigen |
| PSA | Prostate-Specific Antigen |
| RTC | Randomized Controlled Trials |
| SOC | Standard of Care |
| USPSFR | US Preventative Services Task Force |